

From: Morris, Nevitt  
To: paul.gil@sparktx.com; jim.wang@sparktx.com  
Cc: Morris, Nevitt  
Subject: BLA 125610 Spark / Lot Release Specifications Information Request  
Date: Friday, November 24, 2017 12:30:22 PM  
Attachments: image001.png

(File Attachment comment)  
Hi Paul and Jim:

Your revised Lot Release Specifications are acceptable. Please submit a revised Lot Release Protocol based on the specifications agreed by FDA to your BLA, as soon as possible.

Thanks and please acknowledge receipt of this email request.

Nevitt

Nevitt Morris

Nevitt  
Morris,  
RN,  
BSN,  
BS  
Consumer  
Safety  
Officer  
Office  
of  
Tissues  
and  
Advanced  
Therapies  
Center  
for  
Biologics  
Evaluation  
and  
Research  
(CBER)

U.S.  
Food  
and  
Drug  
Administration  
Building  
71,  
Room

4207  
10903  
New  
Hampshire  
Avenue  
Silver  
Spring,  
MD 20993  
Phone: (240)  
402-8269  
Fax: (301)  
595-1303  
Nevitt.Morris@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS  
ADDRESSED  
AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND  
PROTECTED  
FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person  
authorized to deliver  
the document to the addressee, you are hereby notified that any review,  
disclosure,  
dissemination, copying, or other action based on the content of this  
communication is not  
authorized. If you have received this document in error, please  
immediately notify the sender  
immediately by e-mail or phone.  
(Unsigned signature field (Click to sign)) Signature field is unsigned

